The complex landscape of non-coding RNAs in olaparib response and resistance
Poly(ADP-ribose) polymerase inhibitors (PARPi), such as olaparib, have revolutionized the treatment of cancers with deficiencies in homologous recombination repair (HRR), most notably those with BRCA1/2 mutations. However, the clinical efficacy of olaparib is often limited by the development of both...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Elsevier
2026-01-01
|
| Saila: | Cancer Treatment and Research Communications |
| Gaiak: | |
| Sarrera elektronikoa: | http://www.sciencedirect.com/science/article/pii/S2468294226001255 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|